Chronic Obstructive Pulmonary Disease
Conditions
Keywords
Chronic Obstructive Pulmonary Disease, COPD, COPD Exacerbation, Genetic markers COPD, Gene expression in COPD exacerbations, COPD Exacerbation Symptom Reporting, COPD Exacerbation Disease Management, COPD Treatment, Breathing disorders, Emphysema, COPD with Healthy Control comparators for genetic association studies.
Brief summary
The overall purpose of PA-SCOPE is to determine why black and rural residents of Pennsylvania might be at higher risk for deadly, debilitating, and costly hospitalizations for chronic obstructive pulmonary disease (COPD)- and then to show that repeat acute exacerbations in high-risk patients can be reduced with one simple intervention. We believe that 1) COPD patients who are black or who live in rural areas of Pennsylvania are at higher risk of acute exacerbations requiring hospitalization and 2) this elevated risk can be reduced with one simple intervention: access to a 1-800 Temple Call Center where patients can get immediate customized advice on managing COPD exacerbations in their early stages. We will test these beliefs in PA-SCOPE. The collaborators with Temple University Hospital on the PA-SCOPE project are Lancaster General Hospital, Western Pennsylvania Hospital, and the Philadelphia College of Osteopathic Medicine.
Detailed description
* Overall objective: To determine why African American and rural residents of Pennsylvania might be at higher risk for deadly, debilitating, and costly hospitalizations for COPD-and to show that repeat acute exacerbations in high-risk patients can be reduced with one simple intervention--access to a 1-800 Temple Call Center phone number where patients can get immediate customized advice on managing COPD exacerbations in their early stages. * Phase 1: To compare and contrast the influence of race and geographic location in COPD exacerbation in relation to severity, comorbidities, treatment patterns, infection rate. To identify potential risk factors for COPD exacerbations leading to hospitalization. * Phase 2: To reduce hospitalizations and deaths due to COPD exacerbations and to improve patient quality of life, lung function, and everyday activity levels
Interventions
None listed
Sponsors
Pennsylvania Department of Health
Temple University
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Phase 1 & Gene Expression: --Current hospitalization for COPD exacerbation * Phase 1 & 2: COPD & ONE of the following criteria: 1. History of hospitalization for COPD exacerbation, OR 2. Currently on supplemental oxygen, OR 3. History of evaluation for lung transplant or LVRS, OR 4. \>/= 6 months post-LVRS * Phase 1 or 2: 1. Current or former smoker, \>/= 20 pack-yr. smoking history 2. FEV1 \</= 70%; FEV1/FVC \</= 70% 3. Life expectancy of \> 6 months
Exclusion criteria
* \< 20 pack-yr. smoking history * Diagnosis of pulmonary fibrosis, bronchiectasis, mediastinal mass, or presence of a pulmonary mass * Asthma * FEV1 \> 70% or FEV1/FVC \>70%
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase 1 identifies the demographic & genetic factors affecting inpatient hospitalization for COPD exacerbation.Phase 2 documents the number of physician & ER visits, hospitalizations & death related to exacerbations. | Phase 1 is up to 10 weeks. Phase 2 is up to 2 years. |
Secondary
| Measure | Time frame |
|---|---|
| Phase 2 also documents the number, severity, & subject reporting of exacerbations, spirometry changes,& quality of life. | 2 years |
Countries
United States
Outcome results
None listed